Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Collagen density regulates the activity of tumor-infiltrating T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Targetless T cells in cancer immunotherapy

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Peripheral memory T cells specific for Arginase-1

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. undersøges !!

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we evaluated the association between serum biomarkers of collagen and vimentin turnover and outcomes in metastatic melanoma patients treated with the anti-CTLA-4 antibody ipilimumab (IPI).

METHODS: Type III collagen formation (PRO-C3), MMP-degraded type I, type III and type IV collagens (C1M, C3M and C4M), and citrullinated and MMP-degraded vimentin (VICM) were measured with ELISAs in serum from metastatic melanoma patients before (n = 66) and 3 weeks after (n = 52) initiation of IPI treatment. Biomarker levels were associated with Disease Control Rate (DCR) and survival outcomes.

RESULTS: We found that baseline levels of PRO-C3 (p = 0.011), C1M (p = 0.003), C3M (p = 0.013) and C4M (p = 0.027) were significantly elevated in patients with progressive disease (PD). Univariate Cox regression analysis identified high PRO-C3 (p = 0.021) and C4M (p = 0.008) as predictors of poor overall survival (OS) and the biomarkers remained significant when evaluated with other covariates (PRO-C3 (p = 0.049) and C4M (p = 0.046)). Multivariate analysis identified VICM as a predictor of longer OS (p = 0.026). Similarly, a high C3M/PRO-C3 ratio predicted for increased OS (p = 0.034). Only C3M (p = 0.003) and VICM (p < 0.0001) increased 3 weeks after treatment.

CONCLUSIONS: ECM and tissue remodeling quantified in pre-treatment serum were associated with response and survival outcomes in metastatic melanoma patients treated with IPI. This highlights the importance of addressing the ECM and stromal component non-invasively in future ICI studies.

OriginalsprogEngelsk
TidsskriftJournal for ImmunoTherapy of Cancer
Vol/bind6
Udgave nummer1
Sider (fra-til)152
ISSN2051-1426
DOI
StatusUdgivet - 19 dec. 2018

ID: 56133714